Phase 4 Myeloma Trial, Recruiting (NCT05201781)

Phase 4 Myeloma Trial, Recruiting NCT05201781 Sponsor: Janssen Research & Development, LLC Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT05201781 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must have already received at least one dose of a treatment called cilta-cel as part of a previous company-sponsored clinical trial
You must be willing and able to give your consent to take part in this study

Who may not be able to join:

No specific exclusion criteria were listed in the official information provided (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Phone: 844-434-4210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05201781

Sponsor: Janssen Research & Development, LLC

Phase: Phase 4

Status: Recruiting

Condition: Myeloma

Trial contact: 844-434-4210

More information: https://clinicaltrials.gov/study/NCT05201781

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must have already received at least one dose of a treatment called cilta-cel as part of a previous company-sponsored clinical trial
You must be willing and able to give your consent to take part in this study

Who may not be able to join:

No specific exclusion criteria were listed in the official information provided (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Janssen Research & Development, LLC

Registry

ClinicalTrials.gov

Start date

9 March 2022

Est. completion

29 July 2037

Where this trial is recruiting

🇧🇪 Belgium 🇨🇳 China 🇫🇷 France 🇮🇱 Israel 🇯🇵 Japan 🇳🇱 Netherlands 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy; Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic Disorder; Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune Disorder; Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including Hypogammaglobulinemia; Number of Participants with Serious Hematologic Disorder, including Hypogammaglobulinemia; Number of Participants with New Incidence of Grade >= 3 Infection;...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov